|
|
|
| CT Manifestation and Artificial Intelligence Quantitative Analysis of SARS-CoV-2 Omicron Variant |
| LONG Ni-zhe, DING Ru, TANG Bin,et al |
| Medical Imaging Center,The Clinical Hospital of Huaihua,Hengyang Medical School,University of South China,Hengyang Hunan 421001 |
|
|
|
|
Abstract 【Objective】To explore the CT imaging features of patients infected with novel coronavirus Omicron variant,and to quantitatively score the total severity of lesions by artificial intelligence. 【Methods】The clinical data and chest CT imaging characteristics of 23 patients diagnosed with Omicron variant (B.1.1.529) of coronavirus in Huaihua First People's Hospital from March 17 to March 26,2022 were retrospectively analyzed. The volume and proportion of pneumonia were automatically identified and semi-quantitatively calculated by artificial intelligence software to evaluate the application in clinical classification/severity grading. 【Results】Of the 23 patients with Omicron variant of coronavirus,8 cases were positive on chest CT first,which included 6 cases of focal ground-glass opacities and 2 cases of nodular consolidation in the lung.Lesions were mainly distributed in the middle zone of the lung. Five patients had single lobe involvement,of which,4 cases had single lobe involvement in the left lung,1 in the right lung. There were 3 cases involoved in both lungs. No pleural effusion and lymph node enlargement were found in all 8 patients. After artificial intelligence analysis showed that all 8 patients with positive CT examination had the total CT severity score less than or equal to 5 points,including 4 cases with a score of 1 point,1 case with a score of 2 points,2 cases with 3 a score of points and 1 case with a score of 5 points. All patients had mild symptoms,and the CT value of some patients decreased significantly before and after treatment. 【Conclusion】The main imaging manifestations of Omicron variant of coronavirus infection are focal ground-glass opacities and consolidation nodules,which are mainly distributed in the middle zone of the single lung lobe and segment. The prognosis is good,the rate of asymptomatic infection is high,and the degree of pneumonia is mild. The image analyzed by artificial intelligence quantitative characteristics of Omicron variant infection are of great significance for early identification and effective treatment.
|
|
Received: 13 July 2022
|
|
|
|
|
|
[1] MEO S A,MEO A S,AL-JASSIR F F,et al. Omicron SARS-CoV-2 new variant:global prevalence and biological and clinical characteristics[J].Eur Rev Med Pharmacol Sci,2021,25(24):8012-8018.
[2] CDC COVID-19 RESPONSE TEAM. SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States,December 1-8,2021[J].MMWR Morb Mortal Wkly Rep,2021,70(50):1731-1734.
[3] CHENG Q R,FAN M X,HAO J,et al. Chest CT features of children infected by B.1.617.2 (Delta) variant of COVID-19[J].World J Pediatr,2022,18(1):37-42.
[4] DEJNIRATTISAI W,SHAW R H,SUPASA P,et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum[J].Lancet,2022,399(10321):234-236.
[5] SAXENA S K,KUMAR S,ANSARI S,et al. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective[J].J Med Virol,2022,94(4):1738-1744.
[6] TORJESEN I. Covid-19:Omicron may be more transmissible than other variants and partly resistant to existing vaccines,scientists fear[J].BMJ,2021,375:n2943.
[7] CHEN J,WANG R,GILBY N B,et al. Omicron Variant (B.1.1.529):Infectivity,Vaccine Breakthrough,and Antibody Resistance[J].J Chem Inf Model,2022,62(2):412-422.
[8] XU X,YU C,QU J,et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2[J].Eur J Nucl Med Mol Imaging,2020,47(5):1275-1280.
[9] ZHAO H,LU L,PENG Z,et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells[J].Emerg Microbes Infect,2022,11(1):277-283.
[10] LU L,MOK B W,CHEN L L,et al. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or coronavac vaccine recipients[J].Clin Infect Dis,2021,75(1):e822-e826.
[11] SHUAI H,CHAN J F,HU B,et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron[J].Nature,2022,603(7902):693-699.
[12] TALASAZ A H,KAKAVAND H,VAN TASSELL B,et al.Cardiovascular Complications of COVID-19:Pharmacotherapy Perspective[J].Cardiovasc Drugs Ther,2021,35(2):249-259.
[13] HU B,GUO H,ZHOU P,et al. Characteristics of SARS-CoV-2 and COVID-19[J].Nat Rev Microbiol,2021,19(3):141-154. |
|
|
|
2023, Vol. 40 
